Biofilm Control
Biofilm Control - Related Videos
09:03
Growth of Mycobacterium tuberculosis Biofilms
0 Views •
Cited by 79 •
2012
Mycobacterium tuberculosis forms drug tolerant biofilms when cultured in certain conditions. Here we describe methods for culturing M. tuberculosis biofilms and determining the frequency of drug tolerant persisters. These protocols will be useful for further studies into the mechanisms of drug tolerance in M. tuberculosis.
14:42
Remote Magnetic Actuation of Micrometric Probes for in situ 3D Mapping of Bacterial Biofilm Physical Properties
0 Views •
Cited by 5 •
2014
This paper shows an original methodology based on the remote actuation of magnetic particles seeded in a bacterial biofilm and the development of dedicated magnetic tweezers to measure in situ the local mechanical properties of the complex living material built by micro-organisms at interfaces.
10:17
Methodologies for Studying B. subtilis Biofilms as a Model for Characterizing Small Molecule Biofilm Inhibitors
0 Views •
Cited by 28 •
2016
This study presents the development of reproducible methodologies to study biofilm inhibitors and their effects on Bacillus subtilis multicellularity.
03:57
Microtiter Dish Biofilm Formation Assay
0 Views •
Cited by 2184 •
2011
The assay describes a rapid means to measure early biofilm formation in bacteria and fungi. This method uses a microtiter plate as the substratum for microbial biofilm formation, and the biofilm is visualized using crystal violet strain. The assay provides either a qualitative or quantitative assay for early biofilm formation.
03:47
Determination of ROS Production by Neutrophils upon Interaction with Opsonized Biofilm
0 Views •
2025
In this video, we demonstrate an in vitro chemiluminescence assay to detect the generation of reactive oxygen species by neutrophils upon exposure to an opsonized bacterial biofilm.
FAQs
The extracellular matrix can limit antimicrobial access to the microbial cells within a biofilm. Strategies that break down or disrupt this matrix may allow treatment to reach its targets more effectively. This mechanism matters clinically because improved drug access can help reduce microbial persistence, treatment failure, and recurrent infection in affected tissues or medical devices.
Preventing microbial adhesion limits the initial establishment of communities on surfaces, while suppressing cell-to-cell signaling interferes with coordinated biofilm behavior. These approaches address different stages or functions of the microbial community rather than relying only on direct antimicrobial activity. Together, they can support efforts to prevent persistence on wounds, catheters, and implants.
Physical cleaning can remove or disrupt biofilm material, whereas antimicrobial treatment targets the remaining microorganisms. Using both approaches addresses the attached community and the cells it contains more directly than either approach alone. This combination is relevant when structured growth limits drug access, and it may help reduce persistence and improve management of recurrent infection.
A supported approach is to pair physical removal or disruption with an antimicrobial treatment selected for the clinical situation. The process focuses first on reducing attached material and then improving antimicrobial access to remaining microorganisms. Such a workflow can be incorporated into wound-care protocols or strategies for managing contamination associated with catheters and implants.
Medical applications include chronic wound management, device-associated infections, and contamination involving catheters or implants. These settings are important because attached microbial communities can contribute to persistence and recurrent infection. Control strategies provide a framework for reducing that burden while supporting treatment protocols tailored to the affected tissue, device, or surface.
Biofilm control principles can inform antimicrobial coatings that limit microbial establishment on device surfaces and wound-care protocols that combine cleaning with antimicrobial treatment. They also support therapies aimed at matrix disruption or reduced cell-to-cell signaling. These applications connect mechanistic targets with practical efforts to improve drug access, reduce treatment failure, and limit recurrence.